Pharmacogenomics and Pancreatic Cancer Treatment. Optimizing Current Therapy and Individualizing Future Therapy

Soonmo Peter Kang, Muhammad Wasif Saif

Yale Cancer Center, Yale University School of Medicine. New Haven, CT, USA

SUMMARY
Each year, more than 30,000 Americans are diagnosed with pancreatic cancer. We have only made incremental advancements in treatment of pancreatic cancer despite our best efforts. Research has revealed that pancreatic cancer is a genetic disease which is associated with various forms of cancer associated genetic alterations. Identification and understanding of these carcinogenic gene alterations is the base upon which we can overcome drug resistance and develop novel treatment approaches. In this paper, we review current understanding of pharmacogenomics of pancreatic cancer treatment and address future direction of the field.

INTRODUCTION
Each year approximately 30,000 Americans are being diagnosed with pancreatic cancer and nearly all succumb to their disease. It is one of the most challenging solid tumors due to its aggressiveness, debilitating disease-related symptoms, and chemo-resistant biology. At present time, single agent gemcitabine is regarded as the standard of care for advanced pancreatic cancer after a randomized trial showing it superior clinical benefit response over 5-FU. A numerous randomized trials testing gemcitabine doublets failed to show survival benefit by addition of 2nd agent except for one UK study suggesting improved survival with addition of capecitabine [1]. Platinum based agents, topoisomerase inhibitors, taxanes, and novel biological agents have been tried as single agent and as combination with gemcitabine without significant improvement in the outcomes. Our efforts to optimize currently available treatment options and to develop novel agents for pancreatic cancer must start from better understanding of its biology.

Extensive research in the past two decades has revealed that pancreatic cancer is a genetic disease which is associated with various forms of cancer associated genetic alterations. Oncogenes, tumor suppressor genes, and DNA mismatch genes are known to be altered via various modes leading to cancer development, progression, chemo-resistance, and in some cases chemosensitivities of pancreatic cancer [1, 2, 3].

Basics of Pancreatic Cancer Genetics
Oncogenes, when activated, can promote cancer development and progression. K-ras gene is aberrantly activated in up to 90% of pancreatic cancer [2] (Table 1). V-akt murine thymoma viral oncogene homolog 2 (AKT2) gene and nuclear receptor coactivator 3 (NCOA3; also known as AIB1) gene mutations have also been associated with pancreatic cancer.

Tumor suppressor genes are inactivated by homozygous deletion, combination of mutation of one copy and loss of the other copy, and aberrant hypermethylation of gene promoter causing the silencing of the gene.
There are multiple tumor suppressor genes associated with pancreatic cancer and they are mitogen-activated protein kinase kinase 4 (MAP2K4; also known as SEK1), serine/threonine kinase 11 (STK11; also known as LKB1), transforming growth factor, beta receptor II (TGFBR2), tumor protein p53 (TP53) and cyclin-dependent kinase inhibitor 2A (CDKN2A; also known as p16\(^{INK4}\)). DNA mismatch repair genes codes for the proteins that correct errors made randomly during DNA replications, and inactivation of these genes has been associated with various cancers including pancreatic cancers. Identification and understanding of these carcinogenic gene alterations is the base upon which we can overcome drug resistance and develop novel treatment approaches.

### Table 1. Common genetic alterations detected in pancreatic cancer.

<table>
<thead>
<tr>
<th>Class of gene</th>
<th>Gene</th>
<th>Alteration frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncogene</strong></td>
<td>K(^{-})-ras</td>
<td>75-100%</td>
</tr>
<tr>
<td></td>
<td>V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2; HER-2/neu)</td>
<td>10-20%</td>
</tr>
<tr>
<td></td>
<td>V-raf murine sarcoma viral oncogene homolog B1 (BRAF)</td>
<td>10%</td>
</tr>
<tr>
<td></td>
<td>Nuclear receptor coactivator 3 (NCOA3; also known as AIB1)</td>
<td>66%</td>
</tr>
<tr>
<td></td>
<td>V-myb myeloblastosis viral oncogene homolog (MYB)</td>
<td>10%</td>
</tr>
<tr>
<td></td>
<td>V-akt murine thymoma viral oncogene homolog 2 (AKT2)</td>
<td>10-20%</td>
</tr>
<tr>
<td><strong>Tumor suppressor genes</strong></td>
<td>Tumor protein p53 (TP53)</td>
<td>50-75%</td>
</tr>
<tr>
<td></td>
<td>Cyclin-dependent kinase inhibitor 2A (CDKN2A; also known as p16(^{INK4}))</td>
<td>80-95%</td>
</tr>
<tr>
<td></td>
<td>Retinoblastoma 1 (RB1)</td>
<td>60-70%</td>
</tr>
<tr>
<td></td>
<td>SMAD family member 4 (SMAD4; DPC4)</td>
<td>50-55%</td>
</tr>
<tr>
<td><strong>DNA mismatch repair genes</strong></td>
<td>MutL homolog 1, colon cancer, nonpolyposis type 2 (MLH1)</td>
<td>3-15%</td>
</tr>
<tr>
<td></td>
<td>Breast cancer 2, early onset (BRCA2)</td>
<td>7%</td>
</tr>
<tr>
<td><strong>Growth factor and receptors</strong></td>
<td>EGF</td>
<td>60-90%</td>
</tr>
<tr>
<td></td>
<td>EGFR</td>
<td>50-70%</td>
</tr>
<tr>
<td></td>
<td>TGF beta</td>
<td>40-50%</td>
</tr>
</tbody>
</table>

Table 2. Candidate genes with potential pharmacogenomic applications.

<table>
<thead>
<tr>
<th>Chemotherapy agent</th>
<th>Representative candidate gene</th>
<th>Potential implications</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemcitabine</td>
<td>Cytidine deaminase</td>
<td>Drug resistance, toxicity, and survival</td>
<td>[5, 12, 17]</td>
</tr>
<tr>
<td></td>
<td>Deoxycytidine kinase</td>
<td>Drug resistance</td>
<td>[9, 10, 11, 12, 13]</td>
</tr>
<tr>
<td></td>
<td>Ribonucleotide reductase M1 subunit (RRM1)</td>
<td>Drug resistance, and survival</td>
<td>[19]</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>Dihydropyrimidine dehydrogenase (DPD)</td>
<td>Drug toxicity</td>
<td>[32, 33, 34, 35, 36, 37, 38]</td>
</tr>
<tr>
<td></td>
<td>Thymidylate synthetase (TS)</td>
<td>Related to clinical response, drug resistance and toxicity</td>
<td>[42, 43, 44, 51, 52, 54]</td>
</tr>
<tr>
<td></td>
<td>5, 10-methylentetrahydrofolate reductase (MTHFR)</td>
<td>Drug sensitivity</td>
<td>[53]</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1)</td>
<td>Drug toxicity</td>
<td>[56, 57]</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>Excision repair cross complementation group 1 and 2 (ERCC1 and ERCC2)</td>
<td>Drug resistance and survival</td>
<td>[61, 62, 63, 64, 65, 66]</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>Excision repair cross complementation group 1 (ERCC1)</td>
<td>Drug sensitivity</td>
<td>[51]</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>EGFR</td>
<td>Survival</td>
<td>[74, 75, 76]</td>
</tr>
<tr>
<td></td>
<td>K(^{-})-ras</td>
<td>Drug sensitivity</td>
<td>[84]</td>
</tr>
</tbody>
</table>
Therapeutic interventions that are geared to reverse this process are actively being investigated.

**CYTOTOXIC AGENTS (Table 2)**

**Gemcitabine**

5-FU has been the primary agent for palliative treatment of advanced pancreatic cancer until when a randomized trial in mid 1990's showed gemcitabine's superiority over 5-FU in terms of clinical benefits response (24% versus 5%) and 1-year survival (18% versus 2%; P=0.0022). Since then gemcitabine has been the backbone agent in treatment of pancreatic cancer as single agent as well as combinations with other agents. Gemcitabine is relatively well tolerated with common side effects of grade 1 or 2 myelosuppression, fatigue, and gastrointestinal symptoms.

*Mechanism of Action*

Gemcitabine (2’,2’-difluorodeoxycytidine) is a fluorine-substituted deoxycytidine analog. It requires intracellular activation by deoxycytidine kinase to the monophosphate form with eventual metabolism to the cytotoxic nucleotide metabolite difluorodeoxycytidine 5’-triphosphate (dFdCTP). Antitumor activity of gemcitabine is determined by a balance between intracellular activation and degradation and the formation of cytotoxic triphosphate metabolites. Incorporation of dFdCTP metabolite inhibits several DNA polymerases which in turn, interferes with DNA chain elongation, DNA synthesis, and DNA repair. Difluorodeoxycytidine diphosphate (dFdCDP) metabolites inhibit the enzyme ribonucleotide reductase, resulting in decreased levels of essential deoxyribonucleotides for DNA synthesis and function. Incorporation into RNA resulting in alterations in RNA processing and mRNA translation.

*Mechanisms of Drug Resistance*

Currently understood mechanisms of gemcitabine resistance are following:

i. decreased expression of rate limiting enzyme deoxycytidine kinase leading to subsequent decreased activation of gemcitabine;
ii. increased breakdown of drug by catabolic enzymes cytidine deaminase and deoxycytidine monophosphate (dCMP) deaminase;
iii. decreased nucleoside transport of drug into cells;
iv. increased concentration of competing physiologic nucleotide deoxycytidine triphosphate (dCTP), through increased expression of cytidine triphosphate (CTP) synthetase.

*Pharmacogenomics*

Equilibrative nucleoside transporters (hENT), and concentrative nucleoside transporters (hCNT) are proteins that transport gemcitabine to intracellular targets. There are over 58 hCNT single nucleotide polymorphisms (SNPs) identified with 3 SNPs with probable functional impact. *In vitro* studies revealed that gemcitabine is mostly transported to intracellular targets via hENT1 transporters [4]. At least 24 hENT SNPs are also being identified however, the functional impact of these SNPs are being investigated [5, 6]. There are *in vitro* data showing that gemcitabine sensitivity may be significantly altered by inhibiting these transporter proteins [7]. There are studies also suggesting that high expression of hENT1 is associated with survival benefits in pancreatic cancer patients [8].

Deoxycytidine kinase (dCK) is viewed as a rate-limiting enzyme in activating gemcitabine after cellular uptake by transporters. Decreased expression of this enzyme has been reported to be one of the mechanisms of gemcitabine resistance. Correlation between pancreatic cancer's sensitivity to gemcitabine and dCK has been well described [9, 10, 11]. dCK enzyme activity modulating agents are being investigated to design a combination regimen that will optimize gemcitabine's antitumor activity [12, 13].

Studies suggested that infusion of gemcitabine at a fixed dose rate of 10 mg/m²/min had pharmacodynamic advantages over 30 minute infusion by as the rate limiting...
enzyme dCK is known to be saturated at gemcitabine concentration of about 10 mg/m²/min [14]. Phase II trials showed that fixed dose rate gemcitabine can render a trend toward survival benefits [15]. However, the United States Intergroup study have failed to show any significant benefit with fixed dose rate while yielding higher incidence of toxicities [16].

Fixed dose rate infusion of gemcitabine in relation to dCK activity levels may be a complicated yet very important area of study to optimize gemcitabine therapy.

Gemcitabine is inactivated by cytidine deaminase (CDA) and high expression of this enzyme has been associated with gemcitabine resistance and shorter survival [12, 17]. CDA is a polymorphic enzyme and there is one variant allele (208G>A (3*, A70T)) that was identified in Japanese population (allele frequency of 0.037) that had functional impact of CDA. 3* allele appeared to change pharmacokinetic parameters and plasma CDA activities significantly leading to decreased clearance of gemcitabine and increased toxicity. More polymorphisms are being identified and their functional impact will need to be examined [5].

Resistance to gemcitabine is observed in ribonucleotide reductase (RR) M1 and M2 (RRM1 and RRM2) over-expressing lung cancer cells. RRM1 promoter allotypes 37CC-524TT influence overall survival and disease free survival in lung cancer [18]. The diphosphorylated form of gemcitabine inhibits RR and causes some of gemcitabine antitumor activity. M1 subunit of RR is reported to be an important target, and its over expression has been associated with gemcitabine resistance in non small cell lung cancer and pancreatic cancer [19]. Using microarray data, Nakahira et al. [19] have demonstrated that RRM1 gene was the most upregulated gene in the gemcitabine-resistant pancreatic cancer. Furthermore they were able to reduce gemcitabine resistance, in vitro, by RRM1 specific RNAi transfection and subsequent decreased RRM1 expression. They also reported statistically significant association between RRM1 over expression and poorer survival in pancreatic cancer patients [19]. These in vitro and clinical data strongly suggest that not only RRM1 expression level can be used as a predictor of gemcitabine resistance, but also it can be the target to modulate gemcitabine resistance.

Phosphatidylinositol 3-kinase/AKT and NF-kappaB are antiapoptotic signal transduction pathways and liked to chemoresistance of pancreas cancer cells [20]. A reduction of phosphorylated protein kinase B/Akt correlated with the enhancement of gemcitabine induced apoptosis and antitumor activity [21]. NF-kappaB inhibition may enhance the activity of gemcitabine. A numerous lines of evidence suggest that NF-kappaB plays a major role in the growth and chemoresistance of pancreatic cancer. Agents such as curcumin that down regulates NF-kappaB and shown to potentiate antitumor activity of gemcitabine in pancreatic cancer cell lines are future area of clinical investigation [22, 23].

Nakano et al., using RT-PCR analysis, showed that the hENT1 x dCK / RRM1 x RRM2 genes expression level ratio correlated with gemcitabine resistance in pancreatic cancer cell lines indicating the complexity of pharmacogenomics [23]. V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (c-SRC) and focal adhesion kinase (FAK) were also described as genes that are associated with gemcitabine resistance [24].

B-cell CLL/lymphoma 2 (BCL2) over expression is associated with increased in gemcitabine induced apoptosis, and expression of BCL2-associated X protein (BAX) increases sensitivity of pancreatic cancer cell lines to gem and 5-FU [25]. BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) is a member of the BCL2 homology 3 (BH3)-only subfamily of BCL2 family proteins that promote apoptosis. Akada et al. reported a strong association between BNIP3 and intrinsic resistance to gemcitabine in pancreatic cancer [26]. They also showed that by suppressing BNIP3 by small interfering RNA (siRNA), gemcitabine cytotoxicity was reduced in pancreatic cancer.
cell lines [26]. This suggests that BNIP3 could be a potential predictor of gemcitabine sensitivity and furthermore, is a possible target to increase gemcitabine sensitivity. Mutated p53 and BCL2-like 1 (BCL2L1; also known as Bcl-xl) have also been associated with gemcitabine resistance and they were directly involved in apoptosis [27, 28, 29]. Pharmacogenomics of gemcitabine discussed above is being investigated in a clinical trial setting [30].

FLUOROPYRIMIDINES

5-Fluorouracil (5-FU)

*Mechanism of Action*

5-FU is a fluoropyrimidine analog that inhibits the target enzyme thymidylate synthase (TS) by the 5-FU metabolite, fluorodeoxyuridylate (FdUMP). Inhibition of TS results in accumulation of deoxyuridylate (dUMP) which then gets misincorporated into DNA in the form of deoxyuridine triphosphate (dUTP) resulting in inhibition of DNA synthesis and function. Incorporation of the fluorouridine phosphate (FUTP) into RNA results in alterations in RNA processing and translation, and incorporation of fluorodeoxyuridine triphosphate (FdUTP) into DNA results in inhibition of DNA synthesis and function.

*Mechanisms of Drug Resistance*

Mechanisms of drug resistance of 5-FU are following:

i. increased expression of TS;
ii. decreased levels of reduced folate substrate 5, 10-methylenetetrahydrofolate for TS reaction;
iii. decreased incorporation of 5-FU into RNA and DNA;
iv. increased salvage of physiologic nucleosides including thymidine;
v. decreased expression of mismatch repair enzymes;
vi. increased expression of dihydropyrimidine dehydrogenate;
vii. alterations in TS with decreased binding affinity of enzyme for FdUMP.

**Capecitabine**

Capecitabine is a pro-drug that is converted to 5’-deoxy-5-fluourouridine (5’-DFUR) in the liver and tumor tissue in three sequential enzymatic reactions. The final requisite enzyme thymidine phosphorylase (TP) is present at higher levels in tumor compare to normal tissue, thereby having selective antitumor activity. It is the first oral fluoropyrimidine-based anticancer drug that the American FDA has approved as first-line chemotherapy for the indication of metastatic colon cancer [31].

Pharmacogenomics

Earlier pharmacogenomic studies demonstrated that response to 5-FU depends on intra-tumor levels of dehydropyrimidine dehydrogenase (DPD) and TS. High expression of DPD increases 5-FU catabolism (leading to inactivation and elimination) while low levels lead to decreased 5-FU clearance and increased anabolism (cytotoxic pathway) [32, 33, 34, 35, 36, 37, 38]. Similarly, the importance of TS as a target of 5-FU has been underscored by studies demonstrating that incomplete inhibition of TS in the tumor results in reduced chemotherapy effect [39, 40, 41]. Role of increased tumor levels of DPD and/or TS as a mechanism of resistance has been demonstrated in patients treated with 5-FU [42, 43, 44]. Reports also show that high TP in stomach cancer and colon cancer is associated with a bad prognosis [45, 46]. Studies also demonstrated that intra-tumor levels of TP and DPD are good indicators of tumor response to capecitabine [47, 48, 49]. TP is an enzyme that catalyzes the mutual transformation of the pyrimidine nucleosides thymidine and thymine in nucleic acid metabolism. TP is also an enzyme that converts the 5-FU-based anticancer drugs, 5’-DFUR and its derivative, capecitabine, into 5-FU, and it is therefore a limiting factor of the anti-tumor effects of these anticancer drugs. Increased TP results in higher intra-tumor 5-FU level thereby enhancing anti-tumor effect of capecitabine. This preferential activation of capecitabine to 5-FU was demonstrated in
colorectal tumor by Schüller J et al. [49]. Tsukamoto et al. presented in vitro data suggesting that high DPD expression results in lower intra-tumor 5-FU levels through increased degradation [48].

An in vitro study suggested the importance of the ratio of TP and DPD (TP:DPD) in predicting activity of capecitabine against cancer cells. Ishikawa et al. showed that capecitabine can be effective in tumors expressing low TP if DPD expression was low as well [47]. Conversely, capecitabine was not as effective as it was expected to be in tumors with high TP levels if tumors had high DPD levels [47]. Other recent studies suggested correlation between high TP:DPD and anti-cancer activity of 5’-DFUR in human cancer xenograft models [50]. A recent study using 5’-DFUR as adjuvant chemotherapy in colorectal cancer showed that patients with high TP:DPD had better disease-free survival which supported the hypothesis that 5-FU is better activated with high TP levels and degraded to a lesser degree with low DPD levels thereby giving cancer cells maximum exposure to its anticancer activity [50, 51].

Genetic polymorphisms of enzymes involved in the fluoropyrimidines have been described. Exact functional impact of polymorphisms of uridine monophosphate kinase (UMPK) and orotate phosphorylase transferase (OPRT) are unknown as of yet. Polymorphism of TS is better described. At least 5 genotypes have been described. They are characterized by numbers of a 28-bp tandem repeat sequence in the DNA promoter TS enhancer region (TSER). The number of tandem repeats vary from 2 copies (2R) to 9 copies (9R). TS expression level seems to correlate with the number of tandem repeats in in vitro study. Studies have shown that colorectal cancer patients with homozygous 2R TS genotypes have better clinical response with treatment with 5-FU compared to patients with 3R TS genotypes. In terms of toxicities, patients with 3R TS genotypes suffered less 5-FU toxicities probably due to the fact that higher TS level leading to less efficient TS inhibition and decreased cell death in cancer cells as well as normal cells [51, 52].

So far, at least two methylene tetrahydrofolate reductase (MTHFR) polymorphisms have been identified and pre-clinical and clinical data suggested their role as a modifiers of fluoropyrimidine sensitivity [53]. Okumura et al. reported that TS mRNA expression level may be a predictor of chemosensitivity to 5-FU in colorectal cancer [54]. 5-FU catabolic enzymes and their polymorphisms can have significant impact on 5-FU toxicities. Variability in the expression of DPD is a cause of variable 5-FU response and toxicity. Aberrant methylation of DPD promoter region can down regulate DPD activity and consequently increases risk of 5-FU activity in cancer patients [55].

Over 40 different polymorphisms have been identified and 17 mutations were found in patients with severe 5-FU toxicities. DPD*2A is the most commonly noted polymorphism with well established association with decreased DPD activity and 5-FU toxicity [52]. Other SNPs and haplotypes are being identified and their functional impact is being examined. They will offer potential targets to modulate response and tolerance of 5-FU in pancreatic cancer.

The Pharmacogenomic Rationale for a Combination of Gemcitabine and 5-FU in Pancreatic Cancer

A numerous studies examining synergy between 5-FU and gemcitabine revealed that there is no benefit of adding 5-FU to gemcitabine. However, there are phase II and phase III data suggesting benefit of gemcitabine plus capecitabine especially in patients with good performance status. A better patient selection based upon pharmacogenomics of both agents may improve the outcome of patients treated with this doublet chemotherapy.

Irinotecan

Mechanisms of Action

Irinotecan is a semisynthetic derivative of camptothecin, an alkaloid extract from the Camptotheca acuminata tree. It is activated
by the carboxylesterase enzyme to its active form 7-ethyl-10-hydroxycamptothecin (SN-38). SN-38 binds to and stabilizes the type 1 DNA topoisomerase (I-DNA) complex and prevents the religation of DNA after it has been cleaved by topoisomerase I. The collision between this stable complex ("cleavable complex") and the advancing replication fork results in double-strand DNA breaks and cellular death.

**Mechanisms of Drug Resistance**

i. Decreased expression of topoisomerase I and mutations that decreases affinity for the drug are proposed mechanisms of irinotecan resistance;

ii. Increased expression of the multidrug-resistant phenotype with over expression of P170 glycoprotein and subsequent enhanced efflux of drug and decreased intracellular accumulation of drug is also thought to be associated with irinotecan resistance;

iii. Decreased formation of the cytotoxic metabolite SN-38 through decreased activity and or expression of the carboxylase enzyme;

iv. Decreased accumulation of drug into cells by mechanisms not well identified.

**Pharmacogenomics**

The final step of irinotecan metabolism is the inactivation of SN-38 by glucuronidation to SN-38 glucuronide (SN-38G). This step is mediated by uridine diphosphate (UDP) glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1). Recent studies suggested that polymorphisms in the UGT1A1 gene may have an impact on irinotecan toxicities [56]. A variant allele, UGT1A1*28, was associated with irinotecan toxicity by causing reduced conversion of SN-38 in clinical trials. More studies to validate this genotype-phenotype relationship will help us optimize our use of irinotecan based upon the genetic profile in the future [56, 57].

Up to 50% of patients with UGT1A1*28 allele may experience severe irinotecan toxicity, we need to establish genotype-adjusted dosages of irinotecan. genotype-adjusted dosages of irinotecan are on going [57]. ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1; a P-glycoprotein), and ATP-binding cassette, sub-family C (CFTR/MRP), member 2 (ABCC2; a multidrug resistance-associated protein) and ATP-binding cassette, sub-family G (WHITE), member 2 (ABCG2; a breast cancer-resistance protein) are transmembrane proteins that facilitate the cellular efflux of irinotecan and its metabolites. SNPs of ABCB1 gene have been associated with increased exposure to irinotecan and SN-38 and certain haplotypes were associated with decreased renal clearance of irinotecan and SN-38. ABCC2 is the primary transporter involved in hepatobiliary secretion of irinotecan, SN-38, and SN-38G. A ABCC2*2 haplotype, recently, was associated with less irinotecan related toxicities, once again suggesting the possibility of individualizing treatment based upon genetic profiles [57].

The modulation of carboxylesterase expression may impact irinotecan sensitivity. Only 10% of irinotecan is converted to SN-38 by carboxylesterase enzymes [58, 59]. There has been a study that suggested that inducing over expression of carboxylesterase encoding gene in tumor cells, the efficacy of irinotecan can be improved [59].

In general, knowledge of target gene is still lacking. However, the significant achievement of irinotecan pharmacogenomics is a positive example of individualized chemotherapy.

**The Pharmacogenomic Rationale for Combination of Gemcitabine and Irinotecan in Pancreatic Cancer**

Preclinical study in cancer cell lines showed more than additive effect when SN-38 and gemcitabine suggesting synergy between these two agents [60]. However despite promising early phase trial results, phase III trials revealed no added benefit of irinotecan to gemcitabine alone. At present time, there is poor clinical or pharmacogenomic-based rationale in this combining irinotecan with gemcitabine in treatment of pancreatic cancer.

**PLATINUM-BASED AGENTS IN PANCREATIC CANCER TREATMENT**

Platinum based agents such as cisplatin and oxaliplatin have been used in treatment of
pancreatic cancer in combination with gemcitabine with modest benefit evidenced in clinical trials.

**Cisplatin**

*Mechanism of Action*

Cisplatin covalently binds to DNA to produce DNA adducts that results in inhibition of DNA synthesis and function as well as transcription.

*Mechanism of Drug Resistance*

i. Increased DNA repair enzyme activity and deficiency in mismatch repair (MMR) enzymes;

ii. increased inactivation by thiol-containing proteins such as glutathione and glutathione-related enzymes;

iii. alteration in cellular transport resulting in decreased drug accumulation.

*Pharmacogenomics*

Cisplatin resistance is associated with over-expression of excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) gene in ovarian cancer patients. A numerous preclinical and clinical trials have suggested that non small cell cancer patients with low ERCC1 expression levels have better outcome with cisplatin based regimen compared to patients with high ERCC1 expression [61, 62, 63]. Polymorphisms in ERCC1 were associated with prognosis and cisplatin resistance. A study observed that advanced lung cancer patients with one of common SNPs of ERCC1, C8092A, had significantly shorter median survival compared to patients without the variant alleles [64]. Bellmunt *et al.* suggested ERCC1 expression as a prognostic and predictive tool in treatment of bladder cancer. This study reported significantly prolonged survival of patients who were treated with cisplatin-based chemotherapy, hence supporting hypothesis that enhanced DNA repair decreases the benefit of platinum-based chemotherapy [65]. Role of breast cancer 1, early onset (BRCA1) gene in platinum resistance also has been suggested in literatures as well. Deficiency of BRCA1, which has an important role in DNA repair, is associated with resistance to platinum based regimens [66].

*Pharmacogenomic Rationale for Gemcitabine and Cisplatin*

Several *in vitro* studies using different cancer cell lines have suggested synergy between gemcitabine and cisplatin. The mechanism of this synergy is thought to be related to the incorporation of gemcitabine’s active metabolite, difluorodeoxycytidine (dFdC), into DNA that suppresses nuclear excision repair and subsequent increase of cisplatin induced DNA adduct formation [67, 68].

**Oxaliplatin**

*Mechanism of Action*

Oxaliplatin is a third generation platinum compound that binds to DNA to produce DNA adducts resulting in DNA synthesis inhibition as well as inhibition of transcription.

*Mechanism of Resistance*

The mechanisms of oxaliplatin resistance are similar to those of cisplatin.

*Pharmacogenomics*

*In vitro* studies show an antitumor activity of oxaliplatin against pancreatic cancer cell lines [51, 69]. Clinical data show correlation between TS/ERCC1 expression level and overall survival in colorectal cancer patients who were treated with 5-FU/oxaliplatin suggesting the role of ERCC1 in oxaliplatin drug sensitivity in similar mechanism as described above in review of cisplatin drug resistance [51]. Various polymorphisms of glutathione S-transferase pi (GSTP1), *Xeroderma pigmentosum* group D protein, glutathione S-transferase M1 (GSTM1), glutathione S-transferase theta 1 (GSTM1), ERCC1 T19007C, X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1), and epidermal growth factor receptor (EGFR; also known as ErbB1) were associated with clinical outcome of oxaliplatin treatment [51].
**Pharmacogenomic Rationale for Gemcitabine and Oxaliplatin Combination**

The rationale for the use of a combination regimen of gemcitabine plus oxaliplatin stems from various preclinical data. The exposure to gemcitabine 24 hours prior to oxaliplatin showed synergistic effects in antitumor effects in colorectal and leukemia cell lines [70].

The precise mechanisms of this synergy is poorly described, however the incorporation of gemcitabine into DNA subsequently increasing DNA adduct is thought to be the most likely mechanism [71].

**NOVEL APPROACHES: TARGETED AGENTS**

EGFR is over expressed by about 80% pancreatic cancer. It has been associated with poorer survival [72], and it has become an important target for novel anticancer therapy.

**Erlotinib**

Erlotinib is a small molecule tyrosine kinase inhibitor targeting the intracellular domain of EGFR and compete with ATP for binding to the kinase domain, thereby impeding downstream signaling. Erlotinib has shown modest activity as a single agent in pancreatic cancer, and it is currently approved by FDA in combination with gemcitabine in metastatic pancreatic cancer. Skin rash was strongly correlated with better treatment outcome, and a recent data presented at the 2007 ASCO Annual Meeting suggested that the absence of K-ras mutation was associated with better treatment outcome with erlotinib [72].

**Cetuximab**

Cetuximab is a recombinant humanized monoclonal antibody directed against the EGFR. Inhibition of the EGFR signaling pathway results in inhibition of critical mitogenic and anti-apoptotic signals involved in proliferation, growth, invasion/metastasis, angiogenesis, and it also enhances the response to chemotherapy and radiation therapy. Decreased expression of EGFR and mutation in EGFR are thought to be the mechanisms of drug resistance.

Despite promising results from phase II studies, recently presented Phase III trial showed no additive benefit of cetuximab to gemcitabine when this combination regimen was compared to gemcitabine alone [73].

**Pharmacogenomics of Anti EGFR Therapy**

In lung cancer, patients with EGFR mutations had better outcomes with use of erlotinib than patients without the mutation. However, in studies using erlotinib in other cancer types, EGFR mutation status was poorly studied. The modest benefit of erlotinib plus gemcitabine versus gemcitabine alone in a phase III trial warrants more pharmacogenomic investigation. Studies report mere 1.5 to 3.6% frequency of EGFR mutations in pancreatic cancers which is significantly lower that other cancer types. A recent study of Lee *et al.* [74] also observed that the presence of EGFR mutation or increased gene copy number did not significantly influence the survival of pancreatic cancer patients; this is in contrast to well accepted data [75, 76]. This study also suggest that in pancreatic cancer, EGFR mutation may not be predictive of sensitivity to EGFR tyrosine kinase inhibitors [74]. A study by Tzeng *et al.* characterized EGFR mutations in pancreatic adenocarcinomas by using 9 pancreatic carcinoma cell lines and 31 specimens from pancreatic cancer patients, and they observed that EGFR tyrosine kinase domain is highly conserved in pancreatic cancer [77]. This observation may be the explanation of disappointing outcome of anti-EGFR therapy in pancreatic cancer patients. There needs to be more clinical investigations of predictive values of the EGFR mutation and gene copy number on erlotinib or gefitinib response in pancreatic cancer patients in the future.

Various EGFR modulations with cetuximab results in inhibition of DNA repair as well as inhibition of tumor angiogenesis. Recent data by Sung *et al.* [78] suggest that cetuximab may increase sensitivity to DNA damaging chemotherapy agents. Matuzumab is another monoclonal antibody against EGFR that has shown activity in combination with gemcitabine in an early
phase clinical trial [79]. 4-phenethylamino-6- (yderoxyl)phenyl-7H-pyrrolo(2,3-d)pyrimidine (PKI-166), a novel dual inhibitor of EGFR and v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2; also known as HER-2/neu), has been developed and has been promising in preclinical and early clinical trials [80]. Lapatinib is the other dual tyrosine kinase inhibitors tested more extensively in breast cancer patients [81]. Trials in pancreatic cancer are underway.

**ERBB2 (also known as HER-2/neu)**

ERBB2 is an epithelial tumor oncogenes amplified and over expressed in breast, ovary, colon, lung, salivary gland and pancreatic carcinomas. Unlike in breast cancer, significance of ERBB2 over expression is unclear in pancreatic cancer. Despite promising preclinical data showing activity against pancreatic cancer cell lines, orthotopic mouse model, and early clinical trials, Safran et al. showed that trastuzumab and gemcitabine combination is not superior to gemcitabine alone in a clinical trial [82].

**Anti-VEGF Agents**

Over-expression of VEGF is associated with early recurrence after surgery and shorter survival [83]. Based on promising preclinical data, bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, was tested in pancreatic cancer patients. Kindler et al., in the 2007 ASCO Annual Meeting, presented data showing that bevacizumab and gemcitabine combination is not superior to gemcitabine alone in a clinical trial [73]. Sorafinib is a small molecule multi tyrosine kinase inhibitor. The combination of gemcitabine and sorafinib failed to render superiority to gemcitabine alone.

**Pharmacogenomics**

Several polymorphisms of VEGF gene are identified. While there were association of this variant alleles and prognosis of ovarian and breast cancer, the implication of these SNPs in relation to sensitivity to anti-VEGF treatment in poorly studied.

A better understanding of target mutation status and biological consequences will benefit monoclonal antibody development and may guide clinical development and use of these innovative agents.

**Concomitant Inhibition of EGFR and VEGF**

AEE788 is a novel agent that inhibits both EGFR and VEGF receptor tyrosine kinases. *In vitro* studies confirmed its anti-tumor activity. AEE788 in combination with gemcitabine resulted in inhibition of tumor growth, enhancement of apoptotic activity, reduction of microvessel density, and improved survival in orthotopic pancreatic cancer xenograft model [83].

**K-ras as a Target**

K-ras oncogene is activated by point mutations in up to 90% of pancreatic cancer cases with a “signature” localization in codon 12. K-ras mutation in pancreatic cancer is known to develop during the early phase of pancreatic cancer carcinogenesis. Studies suggested that K-ras mutation is associated with poor clinical outcomes. K-ras mutation which can be detected with various means including peripheral blood, has a potential to become a tool for early diagnosis of pancreatic cancer and in order to select patients who will benefit from erlotinib as patients with K-ras mutation are less likely to respond to erlotinib than patients without the mutation [84].

Farnesyl transferase is the enzyme catalyzing the synthesis of ras-protein. Several agents that inhibits this enzyme were developed and showed promising activities in preclinical studies. Tipifarnib was tested as a mono-therapy as well as a combination therapy with gemcitabine, and the results were disappointing. Tipifarnib in phase III trial did not prolong survival in advanced pancreatic cancer compared with gemcitabine alone [85].

**Other Agents**

**Matrix Metalloproteases**

The matrix metalloproteases play an important role in the growth, migration, invasion, metastasis formation, angiogenesis
in cancer. Marimastat showed promising results in pancreatic cancer in early studies, but in phase III double blind study, there was no benefit of adding marimastat [86].

Cyclooxygenase-2 Inhibition

Cyclooxygenase is an enzyme that is known to contribute to the growth of pancreatic cancer. Preclinical data showed marked inhibition of cell proliferation and induction of apoptosis by treatment with a non steroidal anti inflammatory drugs. Celecoxib, a COX-2 inhibitor, significantly enhanced anti tumor activity of chemoradiation in locally advanced pancreatic cancer patients in one study. Other studies failed to show benefit of celecoxib in combination with other chemotherapy agents. In addition, COX-2 inhibitors add significant toxicities, and there are data suggesting that COX-2 inhibitors may increase VEGF production and angiogenesis.

Signal Transduction Inhibitors and Cell Cycle Regulators

2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide (CI-1040) is an inhibitor of mitogen-activated protein kinase kinase 1 (MEK1) and mitogen-activated protein kinase kinase 2 (MAP2K2; also known as MEK2) thereby blocking the phosphorylation of elk-related tyrosine kinase (ERK). A Phase II study showed modest activity against advanced pancreatic cancer with acceptable toxicities. NF-kappa B is over expressed in pancreatic cancer and it has become a target of therapy. Curcumin has antiproliferative activity in pancreatic cancer cell lines. Liposome-encapsulated curcumin decreases tumor growth and neoangiogenesis in preclinical setting. An antisense agent against H-ras (ISIS-2503) has been tried in phase II study in combination with gemcitabine and failed to show its superiority to gemcitabine alone.

Endocrine Manipulation

Anti gastrin therapy and somatostatin analogs have shown encouraging result in pancreatic cancer in preclinical studies. However, clinical trials using hormonal therapies have been largely discouraging.

CONCLUSION AND FUTURE DIRECTION

Therapies currently used in treatment of pancreatic cancer have shown largely disappointing efficacies. New strategies need to be placed in order to move forward. The completion of human genome project has increased interests in the field of pharmacogenomics, and advancement of biotechnology is making application of genomic data more affordable and practical. We are gradually moving toward realizing individualized cancer treatment with pharmacogenomic data that can improve the outcomes of currently available treatments by better patient selection and novel drug administration schema as well as intelligent combinations. However, there still lies great challenges in front of us in practical use of pharmacogenomics data.

Most importantly, we must invest our resources in technological development to identify more important candidate genes and to make those assays available and affordable. With decreasing cost of genotyping, clinical investigators must make concerted efforts to incorporate pharmacogenomics endpoints to large cooperative clinical trials in order to approach required power to test significance of candidate genes.

Keywords Pancreatic Neoplasms; Pharmacogenetics; Therapeutics

Abbreviations 5′-DFUR: 5′-deoxy-5-fluorouridine; ABCB1: ATP-binding cassette, sub-family B (MDR/TAP), member 1; ABCC2: ATP-binding cassette, sub-family C (CFTR/MRP), member 2; ABCG2: ATP-binding cassette, sub-family G (WHITE), member 2; AKT2: v-akt murine thymoma viral oncogene homolog 2; BAX: BCL2-associated X protein; BCL2: B-cell CLL/lymphoma 2; BCL2L1 (also known as Bcl-xl): BCL2-like 1; BRAF: v-raf murine sarcoma viral oncogene homolog B1; BH3: BCL2 homology 3; BNIP3: BCL2/adenovirus E1B 19kDa interacting protein 3; BRCA1: breast cancer 1, early onset; BRCA2: breast cancer 2, early onset; CDA: cytidine deaminase; CDKN2A (also known as
p16\(^{INK4}\): cyclin-dependent kinase inhibitor 2A; Cl-1040: 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenamide; c-SRC: v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog; CTP: cytidine triphosphate; dCK: deoxycytidine kinase; dCMP: deoxycytidine monophosphate; dCTP: deoxycytidine triphosphate; dFdC: difluorodeoxycytidine; dFdCDP: difluorodeoxycytidine diphosphate; dFdCTP: difluorodeoxycytidine 5'-triphosphate; DPD: dehydro-pyrimidine dehydrogenase; dUMP: deoxyuridylate; dUTP: deoxyuridine triphosphate; EGFR (also known as ErbB1): epidermal growth factor receptor; ERBB2 (also known as HER-2/neu): v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; ERCC1: excision repair cross-complementing rodent repair deficiency, complementation group 1; ERK: elk-related tyrosine kinase; FAK: focal adhesion kinase; FdUMP: fluoro-deoxycytidine triphosphate; FUTP: fluorouridine triphosphate; GSTM1: glutathione S-transferase M1; GSTP1: glutathione S-transferase pi; GSTT1: glutathione S-transferase theta 1; hCNT: concentrative nucleoside transporters (humans); hENT: equilibrative nucleoside transporters (humans); I-DNA: type 1 DNA topoisomerase; MAP2K2 (also known as MEK2): mitogen-activated protein kinase kinase 2; MEK1: mitogen-activated protein kinase kinase 1; MAP2K4 (also known as SEK1): mitogen-activated protein kinase kinase 4; MLH1: mutL homolog 1, colon cancer, nonpolyposis type 2; MMR: mismatch repair; MTHFR: methylene tetrahydrofolate reductase; MYB: v-myb myeloblastosis viral oncogene homolog; NCOA3 (also known as AIB1): nuclear receptor coactivator 3; OPRT: orotate phosphorylase transferase; PKI-166: 4-phenethylamino-6-(yderoxyl)phenyl-7H-pyrrolo (2,3-d)pyrimidine; RB1: retinoblastoma 1; RR: ribonucleotide reductase; RRM: ribonucleotide reductase M; siRNA: small interfering RNA; SMAD4 (also known as DPC4): SMAD family member 4; SN-38: 7-ethyl-10-hydroxycamptotecin; SN-38G: SN-38 glucuronide; SNP: single nucleotide polymorphisms; STK11 (also known as LKB1): serine/threonine kinase 11; TGFB2: transforming growth factor, beta receptor II; TP: thymidine phosphorylase; TP53: tumor protein p53; TS: thymidylate synthase; TSER: TS enhancer region; UDP: uridine diphosphate; UGT1A1: UDP glucuronosyl-transferase 1 family, polypeptide A1; UMPK: uridine monophosphate kinase; XRCC1: X-ray repair complementing defective repair in Chinese hamster cells 1

**Conflict of interest** The authors have no potential conflicts of interest

**Correspondence**

Muhammad Wasif Saif
Yale Cancer Center
Yale University School of Medicine
333 Cedar Street, FMP 116
New Haven, Connecticut
USA
Phone: +1-203.737.1569
Fax: +1-203.785.3788
E-mail: wasif.saif@yale.edu

**Reference**


32. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000; 61:199-203. [PMID 10971206]


capcitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-7. [PMID 10755317]


60. Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997; 24:S7-8-S7-16. [PMID 9194474]


